Advertisement

Topics

Eli Lilly's Acute Migraine Treatment Meets Goal in Phase III Study

09:58 EDT 4 Aug 2017 | Drug Discovery Development

Investigators tested the impact of 50 mg, 100 mg, or 200 mg against placebo on these patients.
Staff Author: 

Original Article: Eli Lilly's Acute Migraine Treatment Meets Goal in Phase III Study

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly's Acute Migraine Treatment Meets Goal in Phase III Study"

Quick Search
Advertisement